Sareum Acquires Licence for SRA737

[THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"), AND IS DISCLOSED IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF MAR.]

Sareum Holdings PLC

("Sareum" or the "Company")

Sareum Acquires Licence for SRA737

Cambridge, UK, 13 March 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce that it has acquired the licence for SRA737 following the programme's return from a US-based biopharma company. SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

In December 2024, the licence for SRA737 reverted to the CRT Pioneer Fund ("CPF"), a specialist oncology investment fund and former licensee of SRA737, following the termination of the agreement with the previous US-based licensee. Sareum has now acquired the licence and renegotiated the economic terms under which it will receive a net 63.5% of all future revenues, compared to 27.5% under the former agreement. The remaining interest is divided between CPF and Cancer Research Technology, the commercialisation arm of Cancer Research UK.

Ongoing costs associated with SRA737 will be limited to material and data storage, as well as intellectual property management. Sareum will provide further updates as it evaluates options for the programme.

Dr Stephen Parker, Executive Chairman of Sareum, said: "We believe SRA737 remains a valuable asset, and gaining control of the licence puts us in a stronger position to explore potential partnerships or development opportunities. Given the existing clinical data, we remain optimistic about identifying a path forward that maximises SRA737's value."

Sareum continues to advance its lead programme, SDC-1801, a TYK2/JAK1 inhibitor following the successful completion of a Phase 1 clinical trial in July 2024, which demonstrated an excellent safety profile and promising therapeutic potential for a range of autoimmune diseases.

- Ends -

For further information, please contact: 

About Sareum

Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com